[The clinical value of DNA ploidy in ovarian cancer].
The aim of this study was to correlate the DNA ploidy with clinical parametres in ovarian cancer. For assessment of DNA cellular abnormalities it was used a new method-flow cytometry. Diploidy was stated in 24 cases (55.8%) and aneuploidy in 19 cases (44.2%). In comparing to FIGO staging the frequency of aneuploidy increased from I to IV stage and it was statistic significant. In comparing to vaginal ultrasound examination the difference was not so significant, but the most often aneuploidy was observed in solid tumors. The results of this study show the usefulness of flow cytometry in diagnosis of ovarian cancer.